Drug intelligence / Profile preview

Bi104

Development stage: Preclinical
Lead developer: Biom Pharmaceutical
Modality: Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
Administration: Oral

Overview

Bi104 is an investigational microbiome-based therapy being developed by Biom Pharmaceuticals for the treatment of Angelman Syndrome. Currently in the preclinical stage, Bi104 is designed as a live biotherapeutic product that leverages the company's Diversify platform to modulate the gut-brain axis. The therapy aims to address the core neurological and behavioral symptoms of Angelman Syndrome—a rare genetic disorder caused by the loss of UBE3A gene expression—by restoring microbial balance and influencing the production of neuroactive metabolites. By targeting the gut microbiota, Bi104 seeks to improve motor coordination, reduce seizure activity, and alleviate gastrointestinal issues commonly associated with the condition.

Brand names: Diversify

Beyond the preview

Go deeper on Bi104.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bi104.

Explore the full profile